Updates of incretin‐related drugs for the treatment of type 2 diabetes

Mechanisms of dipeptidyl peptidase‐4 inhibitors, glucagon‐like peptide‐1 receptor agonists and glucagon‐like peptide‐1 receptor/glucose‐dependent insulinotropic polypeptide receptor dual‐agonist in glycemic control and/or weight loss.[Image: see text]

Detalles Bibliográficos
Autores principales: Araki, Hirotaka, Matsumura, Takeshi, Furukawa, Noboru, Araki, Eiichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Update
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889679/
https://www.ncbi.nlm.nih.gov/pubmed/36373430
http://dx.doi.org/10.1111/jdi.13945
_version_ 1784880783747448832
author Araki, Hirotaka
Matsumura, Takeshi
Furukawa, Noboru
Araki, Eiichi
author_facet Araki, Hirotaka
Matsumura, Takeshi
Furukawa, Noboru
Araki, Eiichi
author_sort Araki, Hirotaka
collection PubMed
description Mechanisms of dipeptidyl peptidase‐4 inhibitors, glucagon‐like peptide‐1 receptor agonists and glucagon‐like peptide‐1 receptor/glucose‐dependent insulinotropic polypeptide receptor dual‐agonist in glycemic control and/or weight loss.[Image: see text]
format Online
Article
Text
id pubmed-9889679
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-98896792023-02-02 Updates of incretin‐related drugs for the treatment of type 2 diabetes Araki, Hirotaka Matsumura, Takeshi Furukawa, Noboru Araki, Eiichi J Diabetes Investig Update Mechanisms of dipeptidyl peptidase‐4 inhibitors, glucagon‐like peptide‐1 receptor agonists and glucagon‐like peptide‐1 receptor/glucose‐dependent insulinotropic polypeptide receptor dual‐agonist in glycemic control and/or weight loss.[Image: see text] John Wiley and Sons Inc. 2022-11-14 /pmc/articles/PMC9889679/ /pubmed/36373430 http://dx.doi.org/10.1111/jdi.13945 Text en © 2022 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Update
Araki, Hirotaka
Matsumura, Takeshi
Furukawa, Noboru
Araki, Eiichi
Updates of incretin‐related drugs for the treatment of type 2 diabetes
title Updates of incretin‐related drugs for the treatment of type 2 diabetes
title_full Updates of incretin‐related drugs for the treatment of type 2 diabetes
title_fullStr Updates of incretin‐related drugs for the treatment of type 2 diabetes
title_full_unstemmed Updates of incretin‐related drugs for the treatment of type 2 diabetes
title_short Updates of incretin‐related drugs for the treatment of type 2 diabetes
title_sort updates of incretin‐related drugs for the treatment of type 2 diabetes
topic Update
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889679/
https://www.ncbi.nlm.nih.gov/pubmed/36373430
http://dx.doi.org/10.1111/jdi.13945
work_keys_str_mv AT arakihirotaka updatesofincretinrelateddrugsforthetreatmentoftype2diabetes
AT matsumuratakeshi updatesofincretinrelateddrugsforthetreatmentoftype2diabetes
AT furukawanoboru updatesofincretinrelateddrugsforthetreatmentoftype2diabetes
AT arakieiichi updatesofincretinrelateddrugsforthetreatmentoftype2diabetes

Ejemplares similares